ECO Animal Health Group plc (AIM: EAH)

Market Cap	77.91M
Revenue (ttm)	89.42M
Net Income (ttm)	1.05M
Shares Out	67.74M
EPS (ttm)	0.02
PE Ratio	75.66
Forward PE	48.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,044
Open	n/a
Previous Close	117.50
Day's Range	108.55 - 115.93
52-Week Range	82.67 - 135.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 22, 2024

About ECO Animal Health Group

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, lices, and mange in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1972
• Employees: 227
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EAH

Financial Performance

In 2023, ECO Animal Health Group's revenue was 89.42 million, an increase of 4.82% compared to the previous year's 85.31 million. Earnings were 1.05 million, an increase of 3.97%.